tiprankstipranks
Trending News
More News >
Sensorion SAS (FR:ALSEN)
:ALSEN
Advertisement

Sensorion SAS (ALSEN) AI Stock Analysis

Compare
10 Followers

Top Page

FR:ALSEN

Sensorion SAS

(Frankfurt:ALSEN)

Select Model
Select Model
Select Model
Neutral 49 (OpenAI - 4o)
Rating:49Neutral
Price Target:
€0.50
▲(35.14% Upside)
The overall stock score is primarily influenced by financial performance challenges, including net losses and negative cash flows. Technical analysis shows some short-term positive momentum, but valuation concerns due to a negative P/E ratio and lack of dividend yield weigh heavily on the score.
Positive Factors
Revenue Growth
The company's revenue growth indicates successful market penetration and demand for its therapeutic candidates, which is crucial for long-term sustainability and expansion in the biotechnology sector.
Strong Equity Position
A strong equity base and low debt levels provide financial stability, enabling Sensorion SAS to invest in R&D and withstand market fluctuations, which is vital for growth in the biotech industry.
Positive Gross Profit Margin
A positive gross profit margin suggests efficient cost management in production, which can lead to improved profitability as the company scales and optimizes its operations.
Negative Factors
Substantial Net Losses
Persistent net losses highlight challenges in achieving profitability, which could hinder long-term financial health if not addressed through cost management and revenue enhancement strategies.
Negative Cash Flow
Negative cash flows from operations indicate ongoing financial strain, necessitating improvements in operational efficiency and revenue generation to ensure sustainable business operations.
High Operational Costs
High operational costs reduce profitability and can limit the company's ability to invest in growth opportunities, making cost optimization a priority for future financial success.

Sensorion SAS (ALSEN) vs. iShares MSCI France ETF (EWQ)

Sensorion SAS Business Overview & Revenue Model

Company DescriptionSensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
How the Company Makes MoneySensorion SAS generates revenue primarily through the development and commercialization of its therapeutic candidates. The company's main revenue streams include licensing agreements, collaborations with other pharmaceutical companies, and potentially, sales of approved therapies. Significant factors contributing to its earnings include successful clinical trials, regulatory approvals, and strategic partnerships that facilitate research and development or enhance market access. Sensorion may also benefit from grants and funding opportunities specific to innovation in biotechnology.

Sensorion SAS Financial Statement Overview

Summary
Sensorion SAS shows potential with revenue growth and a solid equity base. However, substantial net losses and negative cash flows present significant challenges. The company needs to focus on cost control and operational efficiency to improve profitability and cash flow stability.
Income Statement
45
Neutral
Sensorion SAS has experienced revenue growth, but profitability remains a concern. While total revenue increased from the previous year, the company continues to operate at a significant net loss. The gross profit margin is positive, indicating effective revenue management, but negative EBIT and EBITDA margins reflect high operational costs. The consistent net loss indicates a need for improved cost management and revenue enhancement strategies.
Balance Sheet
60
Neutral
The company maintains a strong equity position with a low debt-to-equity ratio, suggesting financial stability. Stockholders' equity has improved significantly, indicating investor confidence and capital raising success. However, the persistent net losses continue to erode equity value. The equity ratio is healthy, reflecting a strong capital structure, but ongoing losses could pose risks if not addressed.
Cash Flow
50
Neutral
Sensorion SAS exhibits a challenging cash flow position with negative operating and free cash flows. Despite generating significant financing cash flow, largely from equity raises, the company has been unable to generate positive free cash flow. The free cash flow to net income ratio remains negative, reflecting ongoing operational challenges. A focus on improving operating cash flow is essential for long-term financial health.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue5.84M6.65M5.70M4.93M4.26M2.35M
Gross Profit5.84M6.65M3.79M4.16M3.75M1.94M
EBITDA-30.40M-27.58M-21.33M-22.44M-14.61M-10.26M
Net Income-28.09M-25.97M-22.06M-23.21M-15.14M-8.98M
Balance Sheet
Total Assets73.34M89.28M46.50M38.93M59.02M67.87M
Cash, Cash Equivalents and Short-Term Investments57.06M76.98M36.97M26.20M50.00M62.17M
Total Debt1.55M2.20M2.87M3.76M3.99M3.88M
Total Liabilities16.36M17.14M13.23M17.06M15.03M9.52M
Stockholders Equity56.98M72.14M33.27M21.87M43.98M58.35M
Cash Flow
Free Cash Flow-28.83M-22.45M-21.94M-22.92M-11.81M-5.48M
Operating Cash Flow-28.28M-21.33M-21.07M-21.41M-10.77M-5.31M
Investing Cash Flow-11.15M-11.13M-381.06K-1.54M-1.07M-164.93K
Financing Cash Flow-1.20M62.26M32.20M-820.68K-715.07K37.23M

Sensorion SAS Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.37
Price Trends
50DMA
0.32
Positive
100DMA
0.34
Positive
200DMA
0.43
Negative
Market Momentum
MACD
<0.01
Negative
RSI
73.78
Negative
STOCH
79.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALSEN, the sentiment is Positive. The current price of 0.37 is above the 20-day moving average (MA) of 0.31, above the 50-day MA of 0.32, and below the 200-day MA of 0.43, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 73.78 is Negative, neither overbought nor oversold. The STOCH value of 79.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALSEN.

Sensorion SAS Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
€161.50M4.0758.68%3037.72%
55
Neutral
€149.61M-4.06-223.43%111.76%-22.45%
49
Neutral
€104.31M-40.00%10.87%
48
Neutral
€777.39M-22.92103.70%
48
Neutral
€69.91M-2.02-279.64%52.55%-5.97%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:ALSEN
Sensorion SAS
0.37
-0.38
-51.20%
FR:IPH
Innate Pharma SA
1.75
-0.22
-11.17%
FR:NANO
Nanobiotix
16.90
12.31
268.51%
FR:TNG
Transgene
1.13
0.02
1.44%
FR:OSE
OSE Immunotherapeutics SA
7.04
-1.64
-18.95%
FR:MAAT
MaaT Pharma
4.34
-3.02
-41.03%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 30, 2025